BIOS 62. Future of Scientific Journalism w/ Holden Thorp - Editor-in-Chief @ Science Journals
Holden Thorp became Editor-in-Chief of the Science family of journals on 28 October 2019. He came to Science from Washington University, where he was provost from 2013 to 2019 and professor from 2013 to 2023. He is currently a professor at George Washington University and on leave to serve as the Editor-in-Chief at Science.
Thorp joined Washington University after spending three decades at the University of North Carolina at Chapel Hill (UNC), where he served as the 10th chancellor from 2008 through 2013.
Thorp earned a bachelor of science degree in chemistry from UNC in 1986. He earned a doctorate in chemistry in 1989 at the California Institute of Technology, working with Harry B. Gray on inorganic photochemistry. He completed postdoctoral work at Yale University with Gary W. Brudvig, working on model compounds and reactions for the manganese cluster in the photosynthetic reaction center. He holds an honorary doctor of laws degree from North Carolina Wesleyan College and is a fellow of the American Academy of Arts and Sciences, the National Academy of Inventors, and the American Association for the Advancement of Science.
Thorp cofounded Viamet Pharmaceuticals, which developed VIVJOA (oteseconazole), now approved by the FDA and marketed by Mycovia Pharmaceuticals. Thorp is a venture partner at Hatteras Venture Partners, a consultant to Ancora and Urban Impact Advisors, and is on the board of directors of PBS, the College Advising Corps, and Saint Louis University. He serves on the scientific advisory boards of the Yale School of Medicine and the Underwriters’ Laboratories Research Institutes.
Thorp is the coauthor, with Buck Goldstein, of two books on higher education: Engines of Innovation: The Entrepreneurial University in the Twenty-First Century and Our Higher Calling: Rebuilding the Partnership Between America and its Colleges and Universities, both from UNC Press.
Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.